Breaking News Instant updates and real-time market news.

MLSS

Milestone Scientific

$0.79

-0.035 (-4.24%)

, MOH

Molina Healthcare

$96.24

0.34 (0.35%)

04:55
06/15/18
06/15
04:55
06/15/18
04:55

Achema to hold a conference

ACHEMA 2018 will be held in Frankfurt, Germany on June 11-15.

MLSS

Milestone Scientific

$0.79

-0.035 (-4.24%)

MOH

Molina Healthcare

$96.24

0.34 (0.35%)

TMO

Thermo Fisher

$216.58

0.455 (0.21%)

OPNT

Opiant Pharmaceuticals

$15.71

-0.23 (-1.44%)

TXMD

TherapeuticsMD

$6.87

0.1 (1.48%)

MRK

Merck

$61.56

-0.55 (-0.89%)

MRSN

Mersana Therapeutics

$17.50

0.69 (4.10%)

LOXO

Loxo Oncology

$178.71

-2.37 (-1.31%)

KERX

Keryx

$5.05

-0.03 (-0.59%)

ONCS

OncoSec

$1.44

-0.035 (-2.37%)

PPHM

Ticker changed to CDMO

$0.00

(0.00%)

CBT

Cabot

$64.66

0.72 (1.13%)

IMMU

Immunomedics

$24.02

-0.31 (-1.27%)

BIO

Bio-Rad

$303.52

2.5 (0.83%)

EMN

Eastman Chemical

$107.87

-0.03 (-0.03%)

KANG

iKang Healthcare

$20.50

0.01 (0.05%)

ANTH

Anthera

$0.29

-0.017 (-5.48%)

CLVS

Clovis

$45.02

-0.01 (-0.02%)

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 28

    Jun

  • 10

    Sep

  • 23

    Oct

  • 28

    Oct

  • 13

    Jun

MLSS Milestone Scientific
$0.79

-0.035 (-4.24%)

MOH Molina Healthcare
$96.24

0.34 (0.35%)

03/20/18
PIPR
03/20/18
NO CHANGE
Target $92
PIPR
Overweight
Molina Healthcare price target raised to $92 from $81 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Molina Healthcare to $92 after spending time with management. The company is "ahead of the game in identifying issues and putting the right people in place to fix them," James tells investors in a research note. She thinks communication of this at the May 31 investor day will be a "significant positive catalyst for the stock." The analyst believes Molina's turnaround is progressing and a positive risk/reward is emerging. James reiterates an Overweight rating on the shares and encourages investors to add to positions ahead of the investor day.
02/06/18
PIPR
02/06/18
NO CHANGE
Target $81
PIPR
Overweight
Molina should be bought on weakness from Florida news, says Piper Jaffray
Piper Jaffray analyst Sarah James notes Molina Healthcare this morning announced that it was invited to negotiate for Region 11, but not the remainder of the other seven counties that the company services. Currently, Molina services about 350,000 members in Florida, which the analyst estimate adds $1.06B-$1.48B in revenue and 19c-52c of earnings per share, including 59,000 in region 11. The analyst is surprised with this morning's news, but believes Molina will fight to have this decision overturned. James continues to believe in the company's turnaround story and would be buyers on any weakness today. The analyst has an Overweight rating on the stock. Molina in early trading is down 9% to $79.50.
02/14/18
BMOC
02/14/18
NO CHANGE
Target $85
BMOC
Market Perform
Molina Healthcare price target lowered to $85 from $98 at BMO Capital
BMO Capital analyst Matt Borsch lowered his price target on Molina Healthcare to $85, citing recent losses in Medicaid contracts in New Mexico and Florida on losses in ACA Exchanges. Borsch keeps his Market Perform rating, noting that there have been some signs of improvement in earnings from the company's "core" Medicaid business.
02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Piper sees 'ideal time' to buy Medicaid Managed Care Organizations
Now is an "ideal time" to step in and buy Medicaid Managed Care Organizations Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG), Piper Jaffray analyst Sarah James tells investors in a research note. The stocks are down 12% over the last few weeks due to a combination of the flu and various reform/waiver concerns, the analyst points out. She does not view these as material and says "this is when you double down." Centene is James' top pick.
TMO Thermo Fisher
$216.58

0.455 (0.21%)

02/01/18
LEER
02/01/18
NO CHANGE
Target $239
LEER
Outperform
Thermo Fisher price target raised to $239 from $200 at Leerink
Leerink analyst Puneet Souda raised his price target for Thermo Fisher to $239 from $200 on the back of now higher guide reflected in his estimates and valuation. The analyst reiterates an Outperform rating on the shares as he believes the company is a Life Science Tools leader with an unmatched scale, access to multiple growing end markets and now has a CDMO arm.
01/31/18
COWN
01/31/18
NO CHANGE
Target $220
COWN
Outperform
Thermo Fisher well positioned for 2018 upside, says Cowen
Cowen analyst Doug Schenkel believes Thermo Fisher is well positioned to generate upside in 2018 given its strong free cash flow generation and likelihood of M&A. The analyst said its solid Q4 results has built confidence in the outlook for growth. Schenkel reiterated his Outperform rating and $220 price target on Thermo Fisher shares.
01/09/18
CLVD
01/09/18
NO CHANGE
CLVD
Cleveland Research expects meaningful upside in Q4 for Thermo Fisher
Cleveland Research's said checks indicate Thermo Fisher demand remained strong through year-end and sees an opportunity for 2018 growth to accelerate further.
01/09/18
WELS
01/09/18
NO CHANGE
Target $260
WELS
Outperform
Illumina price target raised to $260 from $250 at Wells Fargo
Wells Fargo analyst Tim Evans raised his price target for Illumina (ILMN) to $260 from $250 after the company delivered a host of positive updates, namely a positive pre-announce of Q4 revenue, above-consensus revenue and EPS guidance for 2018, the official launch of Firefly, the launch of faster library prep consumables, and a collaboration with Thermo Fisher (TMO) to run AmpliSeq on Illumina instruments. The analyst reiterates an Outperform rating on Illumina's shares.
OPNT Opiant Pharmaceuticals
$15.71

-0.23 (-1.44%)

06/11/18
CANT
06/11/18
INITIATION
Target $32
CANT
Overweight
Opiant Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor initiated Opiant Pharmaceuticals with an Overweight and $32 price target.
06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
TXMD TherapeuticsMD
$6.87

0.1 (1.48%)

06/08/18
CANT
06/08/18
NO CHANGE
Target $26
CANT
Overweight
TherapeuticsMD shares do not reflect value of Imvexxy, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views the recent FDA approval of Imvexxy as a major milestone for TherapeuticsMD that sets the company on a course to achieve long-term commercial viability. He reiterates an Overweight rating on the shares with a $26 price target. The investability of TherapeuticsMD stock "has increased considerably," Tanner tells investors in a research note. He believes the current stock price does not fully reflect the value of Imvexxy, "much less that of TX-001."
06/05/18
STFL
06/05/18
NO CHANGE
Target $20
STFL
Buy
Stifel has 'high confidence' in TherapeuticsMD after analyst day
Stifel analyst Annabel Samimy said he left TherapeuticsMD's analyst day with "high confidence" in the launch of Imvexxy and the company's broader commercial strategy ahead of the upcoming expected approval and subsequent launch of TX001HR. The analyst reiterates his Buy rating and $20 price target on TherapeuticsMD shares and "strongly" urges adding to positions at current "depressed levels."
06/05/18
CANT
06/05/18
NO CHANGE
Target $26
CANT
Overweight
TherapeuticsMD market uptake could surprise to upside, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner believes Imvexxy will become an important new treatment for vulvar vaginal atrophy. Given the high degree of dissatisfaction with current genitourinary syndrome of menopause treatments, Imvexxy "could be poised to surprise on the pace of market uptake," Tanner tells investors in a research note. He reiterates an Overweight rating on TherapeuticsMD shares with a $26 price target.
05/21/18
CANT
05/21/18
NO CHANGE
Target $26
CANT
Overweight
Cantor sees high likelihood of approval for TherapeuticsMD's TX-004
Cantor Fitzgerald analyst William Tanner believes the likelihood of FDA approval for TherapeuticsMD's TX-004, the estradiol VagiCap being developed for treating vulvar vaginal atrophy, is high. The FDA action date is May 29. The analyst also believes that a label without the class black box warning is unlikely. The FDA's decision could have a profound impact on how investors view the likelihood of TX-001 approval and management's ability to successfully develop drug products, Tanner tells investors in a research note. He reiterates an Overweight rating on TherapeuticsMD with a $26 price target.
MRK Merck
$61.56

-0.55 (-0.89%)

06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
06/01/18
ROTH
06/01/18
NO CHANGE
Target $400
ROTH
Buy
Roth Capital ups Madrigal price target to $400, examines possible M&A scenarios
Roth Capital analyst Yasmeen Rahimi noted that Madrigal Pharmaceuticals' (MDGL) "impressive" NASH resolution results published yesterday resulted in the stock's value being pushed up to make it the highest among "purely NASH" companies. Among large pharma companies, Rahimi believes those with the strongest metabolic franchises, large R&D teams, and sales forces focused on endocrinologists, gastroenterologists, and hepatologists likely have eyes on NASH assets, listing Merck (MRK), AstraZeneca (AZN), Eli Lilly (LLY) and Novo Nordisk (NVO) as examples. The historical acquisition price for NASH assets ranges from $200M to $1.7B, but Rahimi argues that Madrigal "can set the highest NASH price tag yet," estimating a potential takeout valuation of $5.6B. Rahimi raised her price target on Madrigal shares to $400 from $210 and keeps a Buy rating on the stock.
06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
MRSN Mersana Therapeutics
$17.50

0.69 (4.10%)

05/07/18
BARD
05/07/18
INITIATION
Target $30
BARD
Outperform
Mersana Therapeutics initiated with an Outperform at Baird
Baird initiated Mersana Therapeutics with an Outperform and $30 price target.
05/08/18
05/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Juniper (JNPR) initiated with a Neutral at Rosenblatt. 2. Nice Systems (NICE) initiated with an Equal Weight at Morgan Stanley. 3. Mersana Therapeutics (MRSN) initiated with an Outperform at Baird. 4. iQIYI (IQ) initiated with a Buy at Goldman Sachs. 5. Cubic (CUB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
HCWC
04/25/18
NO CHANGE
Target $33
HCWC
Buy
ADC issues has no read-through to Mersana, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes issues at private company ADC Therapeutics has no read-through to Mersana Therapeutics. ADC Therapeutics recently had two of its antibody drug conjugates programs potentially terminated based on updates on clinicaltrials.gov, Chattopadhyay tells investors in a research note. This includes ADCT-502, which is a HER2-targeted construct, and hence, of potential interest to Mersana investors, the analyst adds. He believes the problems with ADCT-502 are potentially related to the instability of the linker, and has no reflection on Mersana's platform. Chattopadhyay has a Buy rating on Mersana with a $33 price target.
03/19/18
JPMS
03/19/18
DOWNGRADE
Target $19
JPMS
Neutral
Mersana Therapeutics downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jessica Fye downgraded Mersana Therapeutics to Neutral and lowered her price target for the shares to $19 from $23. Dose escalation for XMT-1522 is taking longer than expected, which pushes out data from expansion cohorts to 2019 and a key catalyst for the stock, Fye tells investors in a research note. The analyst does not expect catalysts over 2018 to drive the stock meaningfully higher and sees better opportunities elsewhere.
LOXO Loxo Oncology
$178.71

-2.37 (-1.31%)

06/04/18
MSCO
06/04/18
NO CHANGE
Target $215
MSCO
Overweight
Loxo Oncology price target raised to $215 after ASCO at Morgan Stanley
Morgan Stanley analyst Matthew Harrison said he expects Loxo Oncology shares to trade near $200 in the wake of data on LOXO-292 presented at the ASCO meeting that he said "sets a high bar for competitors." The data positions LOXO-292 to rapidly advance to registration, said Harrison, who raised his market share estimate for LOXO-292 to 70% from 60%, increased his LOXO-292 peak sales estimate to $1B from $700M, and lowered his risk-adjustment, all of which drove his price target on Loxo shares to $215 from $170. He maintains an Overweight rating on Loxo Oncology, which is up 13% to $210.50 in pre-market trading.
06/05/18
IFSG
06/05/18
DOWNGRADE
IFSG
Market Perform
Loxo Oncology downgraded to Market Perform from Strong Buy at IFS Securities
06/05/18
06/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler saying shares have recently recovered, but sales momentum continues to moderate following a deceleration for six consecutive quarters in same-store-sales. 2. Take-Two (TTWO) downgraded to Market Perform from Outperform at BMO Capital with analyst Gerrick Johnson saying he is "concerned" expectations for the Red Dead Redemption 2 release could be overly optimistic and sees a risk to earnings from a potential slowdown in Grand Theft Auto and NBA 2K. 3. Loxo Oncology (LOXO) downgraded to Market Perform from Strong Buy at IFS Securities. 4. Dentsply Sirona (XRAY) downgraded to Neutral from Buy at Northcoast. 5. First Solar (FSLR) downgraded to Neutral from Buy at BofA/Merrill with analyst Julien Dumoulin-Smith saying she expects a "steep" drop in 2018 Chinese solar deployments following China's recent 2018 Solar PV Power Generation Notice, with further declines in 2019/2020 possible. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/04/18
JMPS
06/04/18
NO CHANGE
Target $221
JMPS
Outperform
Loxo Oncology data came in 'far above expectations,' says JMP Securities
JMP Securities analyst Konstantinos Aprilakis said the Phase 1 study data presented on LOXO-292 in patients with RET-altered cancers at the ASCO meeting came in "far above expectations" with respect to both efficacy and safety. Citing the overall response rate in RET fusion cancers of 77%, Aprilakis called the efficacy data "exceedingly impressive" and increased his price target on Loxo Oncology to $221 from $182 following the presentation. Aprilakis maintains his Outperform rating on Loxo shares.
KERX Keryx
$5.05

-0.03 (-0.59%)

ONCS OncoSec
$1.44

-0.035 (-2.37%)

10/19/17
MAXM
10/19/17
NO CHANGE
Target $5
MAXM
Buy
OncoSec data continues to build for Keytruda combination, says Maxim
Maxim analyst Jason McCarthy noted that OncoSec (ONCS) presented "positive" data demonstrating that at 6 months the combination of the company's TAVO with Merck's (MRK) Keytruda in melanoma patients that are non-responders to checkpoint therapy induced a best overall response rate of 50%. The Phase 2b registration study with Merck is now underway and good results would be a "significant incentive" for Merck to support the combination, said McCarthy, who keeps a Buy rating and $5 price target on OncoSec shares.
02/09/18
PIPR
02/09/18
INITIATION
Target $4
PIPR
Overweight
OncoSec initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started OncoSec Medical with an Overweight rating and $4 price target. The company's lead candidate ImmunoPulse in checkpoint inhibitor refractory metastatic melanoma "offers a differentiated approach," the analyst contends. He sees potential for $350M in peak U.S. revenues for IP IL-12 in this initial population following a 2020 launch.
PPHM Ticker changed to CDMO
$0.00

(0.00%)

CBT Cabot
$64.66

0.72 (1.13%)

04/23/18
LOOP
04/23/18
NO CHANGE
Target $80
LOOP
Buy
Cabot weakness on China prices does no reflect fundamentals, says Loop Capital
Loop Capital analyst Chris Kapsch keeps his Buy rating and $80 price target on Cabot, saying the full retracement in its stock price since the initial post-Q1 earnings rally is being attributed to a "recent downdraft in spot Chinese carbon black prices." Kapsch notes however that the China price decline is not indicative of the "the whole story with respect to carbon black fundamentals in that region" - on the contrary, he believes that Cabot's profitability in China will prove sustained.
06/06/18
LOOP
06/06/18
NO CHANGE
Target $80
LOOP
Buy
IMO regulations an eventual positive catalyst for Cabot, says Loop Capital
Loop Capital analyst Chris Kapsch believes the new International Maritime Organization bunker fuel standard, while creating some near-term feedstock sourcing uncertainty, will eventually play out positively for Cabot Corporation. Visibility associated with this benefit, however, may take time to materialize, Kapsch tells investors in a research note. The analyst view Cabot's valuation as "compelling" and sees increasing evidence of the carbon black industry's "positive ongoing fundamental inflection and burgeoning pricing momentum." He keeps a Buy rating on the shares with an $80 price target.
05/09/18
BARD
05/09/18
UPGRADE
BARD
Outperform
Cabot upgraded to Outperform from Neutral at Baird
05/09/18
BARD
05/09/18
UPGRADE
Target $72
BARD
Outperform
Cabot upgraded to Outperform at Baird
As previously reported, Baird analyst Ben Kallo upgraded Cabot to Outperform from Neutral. The analyst believes recent tailwinds in the carbon black market, including competitor curtailments in China, increasing demand, and tight supply, are structural in nature and should contribute to sustained market strength. Kallo raised his price target to $72 from $67 on Cabot shares.
IMMU Immunomedics
$24.02

-0.31 (-1.27%)

05/17/18
WELS
05/17/18
NO CHANGE
WELS
Immunomedics data could support breakthrough designation, says Wells Fargo
Wells Fargo analyst Jim Birchenough believes the abstract data for IMMU132 in hormone-receptor breast cancer could support breakthrough designation and a potential fast-to-market path for an indication that is up to three times bigger than the advanced indication of triple negative breast cancer. The analyst reiterates an Overweight rating on shares of Immunomedics.
06/04/18
WELS
06/04/18
NO CHANGE
Target $31
WELS
Outperform
Immunomedics price target raised to $31 from $25 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Immunomedics to $31 from $25 following review of updated data at the American Society of Clinical Oncology meeting for TROP2-targeted antibody drug conjugate in relapsed/refractory ER+ breast cancer. Overall, the analyst believes that response rate of 31% with median response duration of 7.4 months is in line with that supporting breakthrough designation and accelerated approval filing in triple negative breast cancer, and believes the shares are undervalued relative to aggregate opportunity in TNBC, ER+ breast cancer, urothelial cancer and other TROP2+ cancers. Birchenough reiterates an Outperform rating on the stock.
01/24/18
JEFF
01/24/18
NO CHANGE
Target $22
JEFF
Buy
Immunomedics price target raised to $22 from $16 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Immunomedics to $22 saying his analysis suggests a 98% FDA approval probability of IMMU-132. The shares could be worth $27 on approval, Andrews tells investors in a research note. He keeps a Buy rating on Immunomedics.
06/06/18
RILY
06/06/18
INITIATION
Target $53
RILY
Buy
Immunomedics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Immunomedics with a Buy rating and $53 price target and added the shares to his firm's Alpha Generator list. The company has the makings of a blockbuster cancer drug, Kumar tells investors in a research note.
BIO Bio-Rad
$303.52

2.5 (0.83%)

02/28/18
JEFF
02/28/18
NO CHANGE
Target $325
JEFF
Buy
Bio-Rad price target raised to $325 from $300 at Jefferies
Jefferies analyst Brandon Couillard raised his price target for Bio-Rad Laboratories to $325 saying the second half of 2017 margin ramp and initial 2018 outlook "should quell debate" over the company's ability to execute and the relevancy of its 2020 goals. Couillard says Bio-Rad remains his top pick and the "most compelling absolute value we can find." He keeps a Buy rating on the shares following the company's Q4 results.
02/28/18
DBAB
02/28/18
NO CHANGE
Target $325
DBAB
Buy
Bio-Rad price target raised to $325 from $309 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Bio-Rad Laboratories to $325 citing the better than expected Q4 results. The analyst says the company's guidance for even better margin improvement in 2018 supports his Buy thesis.
03/20/18
WELS
03/20/18
NO CHANGE
Target $290
WELS
Outperform
Bio-Rad price target raised to $290 from $280 at Wells Fargo
Wells Fargo analyst Tim Evans raised his price target for Bio-Rad to $290 from $280 to reflect an increase in the value of the company's stake in Sartorius. The analyst reiterates an Outperform rating on the shares.
02/22/18
JEFF
02/22/18
NO CHANGE
Target $300
JEFF
Buy
Jefferies sees low valuation and expectations into Bio-Rad's Q4 print
Jefferies analyst Brandon Couillard says Bio-Rad Laboratories' valuation is low and expectations appear low while the company's fundamentals are improving. He thinks the street has overlooked the recovery in Sartorius, which he notes has added $800M of value year-to-date for the company. Couillard has a positive bias into the Q4 print and sees a "clear path to margin expansion upside" in 2018. He keeps a Buy rating on Bio-Rad with a $300 price target.
EMN Eastman Chemical
$107.87

-0.03 (-0.03%)

02/05/18
RHCO
02/05/18
NO CHANGE
Target $105
RHCO
Hold
Eastman Chemical price target raised to $105 from $90 at SunTrust
SunTrust analyst James Sheehan raised his price target on Eastman Chemical to $105 after the company's Q4 earnings beat, saying the strengthening of the global macro environment are leading to tailwinds in commodity spreads. The analyst also points to "sustainable" environmental enforcement trends in China, as the company benefited from competitor shutdowns in tire additives and olefin derivatives. Sheehan keeps his Hold rating on Eastman Chemical, noting that valuations on the stock appear to be fair.
04/30/18
RBCM
04/30/18
NO CHANGE
Target $107
RBCM
Sector Perform
Eastman Chemical price target raised to $107 from $103 at RBC Capital
RBC Capital analyst Arun Viswanathan raised his price target on Eastman Chemical to $107 after the company posted a "solid" quarter that demonstrated its "portfolio is working". Viswanathan keeps his Sector Perform rating, adding that the guidance may have been light as the company is facing more difficult relative comps in the second half of the year. The analyst believes valuation on the stock is fair after shares' gains of 12% year-to-date.
02/20/18
WELS
02/20/18
NO CHANGE
Target $115
WELS
Outperform
Eastman Chemical price target raised to $115 from $108 at Wells Fargo
Wells Fargo analyst Frank Mitsch raised his price target for Eastman Chemical to $115 from $108 and added it to his firm Priority Stock List after meeting with management. The analyst says he is now more bullish on near and mid-term fundamentals, and reiterates an Outperform rating on the shares.
04/30/18
RBCM
04/30/18
NO CHANGE
Target $107
RBCM
Sector Perform
Eastman Chemical price target raised to $107 from $103 at RBC Capital
RBC Capital analyst Arun Viswanathan raised his price target on Eastman Chemical to $107 after the company posted a "solid" quarter that demonstrated its "portfolio is working". Viswanathan keeps his Sector Perform rating, adding that the guidance may have been light as the company is facing more difficult relative comps in the second half of the year. The analyst believes valuation on the stock is fair after shares' gains of 12% year-to-date.
KANG iKang Healthcare
$20.50

0.01 (0.05%)

ANTH Anthera
$0.29

-0.017 (-5.48%)

03/12/18
PIPR
03/12/18
DOWNGRADE
PIPR
Underweight
Anthera downgraded to Underweight from Overweight at Piper Jaffray
06/01/18
HCWC
06/01/18
NO CHANGE
HCWC
Buy
AzurRx hiring experienced CMO adds validation to MS1819, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju noted that AzurRx BioPharma (AZRX) hired Dr. James Pennington, who was previously Chief Medical Officer and later Senior Clinical Fellow at Anthera Pharmaceuticals (ANTH), as the company's CMO. The fact that an experience CMO such as Dr. Pennington agreed to join AzurRx adds incremental validation to MS1819, the company's candidate for EPI associated with chronic pancreatitis and cystic fibrosis, said Selvaraju, who keeps a Buy rating on AzurRx shares.
03/06/18
HCWC
03/06/18
NO CHANGE
Target $3
HCWC
Buy
Anthera risk/reward attractive into March data, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein continues to like the risk/reward equation on shares of Anthera Pharmaceuticals heading into this month's Sollpura data readout. The analyst believes the Result trial's more dose-tailoring, time, and patients allow greater room for optimization and achieving max therapeutic effect. He believes "very little positivity" is now reflected in the shares, and expects an "outsized move to the upside" should a positive result be announced later this month. Fein has a Buy rating on Anthera with a $3 price target.
03/12/18
03/12/18
DOWNGRADE
Target $0.1

Underweight
Anthera downgraded to Underweight with 10c target at Piper Jaffray
As previously reported, Piper Jaffray analyst Edward Tenthoff double downgraded Anthera to Underweight from Overweight after the company's Phase 3 trial of Sollpura missed the primary non-inferiority endpoint of Coefficient of Fat Absorption in patients with cystic fibrosis with exocrine pancreatic insufficiency, or CF-EPI. Tenthoff, who expects Anthera will further reduce headcount in order to focus on strategic alternatives, cut his price target on Anthera shares to 10c from $4 based on his value for blisibimod of $5M, less the company's net debt. In morning trading, Anthera has plunged 80% to 52c per share.
CLVS Clovis
$45.02

-0.01 (-0.02%)

04/09/18
RHCO
04/09/18
NO CHANGE
Target $90
RHCO
Buy
Clovis price target raised to $90 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Clovis to $90 after the company's Rubraca was approved for second line maintenance therapy in ovarian cancer. Lawson adds that while the approval was "mostly expected", his new price target reflects an increase in the probability of success and deeper conviction for further indicators, while also pointing to a generally broader use of PARP inhibitors. The analyst keeps his Buy rating on Clovis.
04/06/18
PIPR
04/06/18
NO CHANGE
PIPR
Neutral
Clovis approval underscores rising competition facing Zejula, says Piper Jaffray
Prior to today's announcement that Clovis' (CLVS) label for its PARP inhibitor Rubraca has been expanded to include maintenance therapy in ovarian cancer, AstraZeneca's (AZN) Lynparza and Tesaro's (TSRO) Zejula were the only two PARP inhibitors approved in the maintenance setting, noted Piper Jaffray analyst Christopher Raymond. While Clovis' approval is not a surprise, it does underscore the intensifying competitive pressure facing Zejula, he said. Raymond, who said PARP inhibitors will primarily be differentiated on safety and added that this does not favor Zejula, keeps a Neutral rating on Tesaro.
02/27/18
LEHM
02/27/18
NO CHANGE
Target $85
LEHM
Overweight
Clovis price target lowered to $85 from $105 at Barclays
Barclays analyst Paul Choi lowered his price target for Clovis Oncology to $85 citing slower market transition to maintenance following the company's Q4 results. The analyst thinks the stock "will likely stay in a holding pattern" prior to the label expansion in the U.S. and an initial treatment indication approval in Europe, both of which are anticipated by Q2. Choi keeps an Overweight rating on Clovis shares.
02/27/18
RHCO
02/27/18
NO CHANGE
Target $85
RHCO
Buy
Clovis price target lowered to $85 from $95 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Clovis to $85 after the company's Q4 earnings, saying that since the revenues of Rubraca were "essentially flat", the Street was likely to reset growth expectations. The analyst adds that he has pushed back his view of commercialization in prostate and additional settings, but still believes the stock is "attractively positioned with reset revenues, and potentially positive news flows in the near term". Lawson keeps his Buy rating on Clovis.

TODAY'S FREE FLY STORIES

01:45
06/21/18
06/21
01:45
06/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

RYTM

Rhythm Pharmaceuticals

$26.45

0.21 (0.80%)

22:08
06/20/18
06/20
22:08
06/20/18
22:08
Syndicate
Rhythm Pharmaceuticals 5.732M share Secondary priced at $26.42 »

Morgan Stanley,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 21

    Jun

AMCX

AMC Networks

$67.45

1.28 (1.93%)

22:06
06/20/18
06/20
22:06
06/20/18
22:06
Downgrade
AMC Networks rating change at Bernstein »

AMC Networks downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

APTX

Aptinyx

$0.00

(0.00%)

20:45
06/20/18
06/20
20:45
06/20/18
20:45
Syndicate
Aptinyx 6.4M share IPO priced at $16.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

AVRO

AvroBio

$0.00

(0.00%)

20:44
06/20/18
06/20
20:44
06/20/18
20:44
Syndicate
AvroBio 5.25M share IPO priced at $19.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

TV

Televisa

$18.25

0.51 (2.87%)

20:43
06/20/18
06/20
20:43
06/20/18
20:43
Downgrade
Televisa rating change at Scotiabank »

Televisa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

Cemex

$6.33

0.115 (1.85%)

20:42
06/20/18
06/20
20:42
06/20/18
20:42
Upgrade
Cemex rating change at Santander »

Cemex upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$164.49

0.74 (0.45%)

20:41
06/20/18
06/20
20:41
06/20/18
20:41
Downgrade
Parker-Hannifin rating change at Wells Fargo »

Parker-Hannifin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMT

Kennametal

$37.44

1.11 (3.06%)

20:41
06/20/18
06/20
20:41
06/20/18
20:41
Downgrade
Kennametal rating change at Wells Fargo »

Kennametal downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNT

Syntel

$34.07

0.65 (1.94%)

20:40
06/20/18
06/20
20:40
06/20/18
20:40
Downgrade
Syntel rating change at Wells Fargo »

Syntel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MGTA

Magenta Therapeutics

$0.00

(0.00%)

20:28
06/20/18
06/20
20:28
06/20/18
20:28
Syndicate
Magenta Therapeutics 6.667M share IPO priced at $15.00 »

The deal priced in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

XERS

Xeris Pharmaceuticals

$0.00

(0.00%)

20:26
06/20/18
06/20
20:26
06/20/18
20:26
Syndicate
Xeris Pharmaceuticals 5.7M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

KR

Kroger

$26.21

0.21 (0.81%)

, DRI

Darden

$93.27

-1.34 (-1.42%)

20:25
06/20/18
06/20
20:25
06/20/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$26.21

0.21 (0.81%)

DRI

Darden

$93.27

-1.34 (-1.42%)

CMC

Commercial Metals

$23.67

0.44 (1.89%)

PDCO

Patterson Companies

$22.54

0.07 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

  • 21

    Jun

  • 21

    Jun

  • 28

    Jun

  • 10

    Jul

IIIV

i3 Verticals

$0.00

(0.00%)

20:24
06/20/18
06/20
20:24
06/20/18
20:24
Syndicate
i3 Verticals 6.65M share IPO priced at $13.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

KZR

Kezar Life Sciences

$0.00

(0.00%)

20:23
06/20/18
06/20
20:23
06/20/18
20:23
Syndicate
Kezar Life Sciences 5M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

LPL

LG Display

$8.91

-0.015 (-0.17%)

20:08
06/20/18
06/20
20:08
06/20/18
20:08
Periodicals
LG Display discussing early retirement options for workers, Bloomberg reports »

LG Display is considering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGO

Eldorado Gold

$1.13

-0.02 (-1.75%)

20:05
06/20/18
06/20
20:05
06/20/18
20:05
Hot Stocks
Eldorado Gold provides update on Lamaque exploration and development »

Eldorado Gold is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, RSX

Market Vectors Russia ETF

$20.52

0.22 (1.08%)

19:43
06/20/18
06/20
19:43
06/20/18
19:43
Periodicals
Trump planning to meet with Russia's Putin in Europe next month, Bloomberg says »

Donald Trump and…

SPX

S&P 500

$0.00

(0.00%)

RSX

Market Vectors Russia ETF

$20.52

0.22 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEO

CNOOC

$163.48

2.345 (1.46%)

19:29
06/20/18
06/20
19:29
06/20/18
19:29
Periodicals
CNOOC to proceed with expansion in Canada's oil sands, Reuters reports »

CNOOC's Nexen Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$134.34

-1.815 (-1.33%)

19:14
06/20/18
06/20
19:14
06/20/18
19:14
Periodicals
Toyota to reduce marketing costs to fund new research, Reuters reports »

Toyota Motors has started…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$202.08

4.62 (2.34%)

, GOOG

Alphabet

$1,169.38

1.52 (0.13%)

19:06
06/20/18
06/20
19:06
06/20/18
19:06
Periodicals
FTC chair wants to explore market power of big internet firms, Reuters says »

New U.S. Federal Trade…

FB

Facebook

$202.08

4.62 (2.34%)

GOOG

Alphabet

$1,169.38

1.52 (0.13%)

GOOGL

Alphabet Class A

$1,183.83

5.54 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

RYAAY

Ryanair

$117.11

3.54 (3.12%)

19:01
06/20/18
06/20
19:01
06/20/18
19:01
Periodicals
IAG, Ryanair preparing EU legal challenge over air traffic strikes, FT reports »

IAG and Ryanair are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNED

Barnes & Noble Education

$6.78

0.3 (4.63%)

, MU

Micron

$58.97

-0.26 (-0.44%)

19:00
06/20/18
06/20
19:00
06/20/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Barnes…

BNED

Barnes & Noble Education

$6.78

0.3 (4.63%)

MU

Micron

$58.97

-0.26 (-0.44%)

SCS

Steelcase

$15.55

0.2 (1.30%)

LITE

Lumentum

$56.45

0.8 (1.44%)

HPQ

HP Inc.

$23.31

-0.215 (-0.91%)

THO

Thor Industries

$104.81

6.5 (6.61%)

GLW

Corning

$28.40

0.015 (0.05%)

AOBC

American Outdoor Brands

$13.22

0.13 (0.99%)

LMNR

Limoneira

$26.65

0.63 (2.42%)

VERI

Veritone

$21.52

-0.64 (-2.89%)

TRUP

Trupanion

$41.07

0.8 (1.99%)

ARRS

Arris

$25.51

0.015 (0.06%)

WIX

Wix.com

$107.70

1.15 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 21

    Jun

  • 22

    Jun

  • 09

    Jul

  • 10

    Jul

  • 11

    Jul

  • 12

    Jul

  • 21

    Jun

  • 21

    Jun

  • 21

    Jun

DIS

Disney

$107.28

1.08 (1.02%)

18:55
06/20/18
06/20
18:55
06/20/18
18:55
Periodicals
Disney puts future 'Star Wars' spinoffs on hold, Collider reports »

Disney's Lucasfilm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$276.00

0.52 (0.19%)

, SPX

S&P 500

$0.00

(0.00%)

18:54
06/20/18
06/20
18:54
06/20/18
18:54
Periodicals
Trump sees U.S. quarterly GDP going much higher, Bloomberg reports »

Says the head of U.S.…

SPY

SPDR S&P 500 ETF Trust

$276.00

0.52 (0.19%)

SPX

S&P 500

$0.00

(0.00%)

X

U.S. Steel

$35.72

0.56 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.